|
1.
|
|
14 p, 13.9 MB |
ScipionTomo : Towards cryo-electron tomography software integration, reproducibility, and validation
/
Jiménez de la Morena, Jorge (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology) ;
Conesa Mingo, Pablo (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology) ;
Fonseca-Reyna, Yunior César (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology) ;
de Isidro-Gómez, Federico P. (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology) ;
Herreros, David (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology) ;
Fernández-Giménez, Estrella (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology) ;
Střelák, David (Masaryk University) ;
Moebel, Emmanuel (Institut National de Recherche en Informatique et en Automatique) ;
Buchholz, Tim Oliver (Center for Systems Biology Dresden) ;
Jug, Florian (Fondazione Human Technopole) ;
Martínez-Sánchez, Antonio (University of Oviedo. Department of Computer Sciences) ;
Harastani, Mohamad (Sorbonne Université) ;
Jonic, Slavica (Sorbonne Université) ;
Conesa, José Javier (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology) ;
Cuervo, Ana (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology) ;
Losana, Patricia (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology) ;
Sánchez-Caballero, Ignacio (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology) ;
Iceta Tena, Mikel (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology) ;
del Cano, Laura (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology) ;
Gragera, Marcos (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology) ;
Melero, Roberto (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology) ;
Sharov, Grigory (MRC Laboratory of Molecular Biology. Structural Studies Division) ;
Castaño-Díez, Daniel (University of Basel. Biozentrum) ;
Koster, Abraham J. (University of Leiden. Ultrastructural and Molecular Imaging) ;
Piccirillo, Jonathan G. (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology) ;
Vilas, Jose Luis (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology) ;
Oton, Joaquin (ALBA Laboratori de Llum de Sincrotró) ;
Marabini, Roberto (Universidad Autònoma de Madrid. Escuela Politécnica Superior) ;
Sorzano, Carlos Oscar S. (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology) ;
Carazo Garcia, José María (Consejo Superior de Investigaciones Científicas. National Center of Biotechnology)
Image processing in cryogenic electron tomography (cryoET) is currently at a similar state as Single Particle Analysis (SPA) in cryogenic electron microscopy (cryoEM) was a few years ago. Its data processing workflows are far from being well defined and the user experience is still not smooth. [...]
2022 -  10.1016/j.jsb.2022.107872
Journal of structural biology, Vol. 214, Issue 3 (September 2022) , art. 107872
|
|
|
2.
|
|
11 p, 779.0 KB |
Antitubercular drugs for an old target : GSK693 as a promising InhA direct inhibitor
/
Martínez-Hoyos, María (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Perez-Herran, Esther (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Gulten, Gulcin (Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA) ;
Encinas, Lourdes (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Álvarez-Gómez, Daniel (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Alvarez, Emilio (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Ferrer-Bazaga, Santiago (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
García-Pérez, Adolfo (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Ortega, Fátima (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Angulo-Barturen, Iñigo (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Rullas-Trincado, Joaquin (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Blanco Ruano, Delia (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Torres, Pedro (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Castañeda, Pablo (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Huss, Sophie (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Fernández Menéndez, Raquel (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
González del Valle, Silvia (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Ballell, Lluis (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Barros, David (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Modha, Sundip (Target and Pathway Validation, Molecular Discovery Research, GlaxoSmithKline, Stevenage, Herts, UK) ;
Dhar, Neeraj (School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne 1015, Switzerland) ;
Signorino-Gelo, François (Target and Pathway Validation, Molecular Discovery Research, GlaxoSmithKline, Stevenage, Herts, UK) ;
McKinney, John D. (Target and Pathway Validation, Molecular Discovery Research, GlaxoSmithKline, Stevenage, Herts, UK) ;
García-Bustos, Jose Francisco (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Lavandera, Jose Luis (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Sacchettini, James C. (Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA) ;
Jimenez, M. Soledad (Instituto de Salud Carlos III) ;
Martín-Casabona, Nuria (Hospital Universitari Vall d'Hebron) ;
Castro-Pichel, Julia (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Mendoza-Losana, Alfonso (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Universitat Autònoma de Barcelona
Despite being one of the first antitubercular agents identified, isoniazid (INH) is still the most prescribed drug for prophylaxis and tuberculosis (TB) treatment and, together with rifampicin, the pillars of current chemotherapy. [...]
2016 - 10.1016/j.ebiom.2016.05.006
EBioMedicine, Vol. 8 (may 2016) , p. 291-301
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
